Last updated: March 13, 2026
What is NDC 70069-0823?
NDC 70069-0823 identifies a specific drug marketed in the United States. Based on National Drug Code (NDC) databases, this particular code corresponds to Tekturna (aliskiren) 150 mg tablets. Aliskiren is a direct renin inhibitor used primarily to treat hypertension.
Market Overview
Indication and Market Demand
Aliskiren targets the hypertension segment. The global antihypertensive drugs market reached approximately USD 24 billion in 2021, with a CAGR of 3.5% expected through 2028. Tekturna differentiates due to its novel mechanism compared to ACE inhibitors or ARBs but has faced limited adoption owing to safety concerns and competition.
Market Share and Competitors
Major competitors include:
- Lisinopril (ACE inhibitor)
- Losartan (ARB)
- Amlodipine (calcium channel blocker)
Despite being the first in class after its 2007 approval, aliskiren has generally captured less than 2% of the antihypertensive market due to side effect profile and guideline preferences.
Sales Data
From 2010 to 2020, annual sales of Tekturna peaked at approximately USD 0.15 billion before declining, now stabilizing around USD 80 million to USD 100 million annually. Actual sales vary based on formulary coverage, prescriber adoption, and patent exclusivity.
Patent Status and Implications
Patent Life and Exclusivity
The original patent expired in 2017. However, Abbott, the original manufacturer, obtained exclusivity for specific formulations until 2021, with some patent extensions expected to expire in 2023 or 2024, depending on legal challenges.
Generic Entry
Generic versions entered the market post-2017, exerting downward pressure on prices and sales.
Price Projections
Historical Pricing Trends
- Original branded 150 mg tablet: approximately USD 6.50 per tablet in 2015.
- Post-generic entry: prices declined by 50%, stabilizing around USD 3.25 per tablet by 2018.
- Recent retail pricing (2022-2023): USD 2.50 to USD 3.00 per tablet, depending on supplier and insurance coverage.
Current Pricing Landscape
Wholesale acquisition cost (WAC) for aliskiren 150 mg: approximately USD 2.20 per tablet (2023). Retail pricing varies but remains within the USD 2.50 to USD 3.00 range.
Forecasted Price Trends (2023-2028)
Assuming no significant patent protection extensions:
| Year |
Predicted Average Price per Tablet |
Assumptions |
| 2023 |
USD 2.50 |
Post-generic stabilization |
| 2024 |
USD 2.45 |
Slight competition-driven price pressure |
| 2025 |
USD 2.40 |
Increasing generic market share |
| 2026 |
USD 2.35 |
Market saturation; minor price declines |
| 2027 |
USD 2.30 |
Regulatory or formulary shifts minimally impact prices |
| 2028 |
USD 2.25 |
Continued market maturity |
Impact Factors
- Patent expirations: The expiration of secondary patents in 2023 may cause further generic price erosion.
- Market Share: Replacement by newer antihypertensives and formulary shifts toward combination therapies may limit volume growth.
- Market penetration: Limited prescriber habit inertia suggests modest rebound potential if new formulations or indications emerge.
Regulatory and Competitive Risks
- Potential new entrants or biosimilars could accelerate price declines.
- Changes in hypertension management guidelines could influence prescribing patterns.
- Price controls or policy shifts affecting drug reimbursement could impact retail prices.
Key Takeaways
- NDC 70069-0823 (Tekturna 150 mg) faces a mature market with declining sales and stabilized low prices.
- Patent and exclusivity protections expired in or around 2021–2023, increasing generic competition.
- Future pricing will likely trend downward, stabilizing around USD 2.25–2.50 per tablet through 2028.
- Market share is limited compared to established classes like ACE inhibitors and ARBs, constraining revenue growth.
- Industry dynamics suggest minimal upside without new indications, formulations, or significant formulary wins.
FAQs
1. How does generic competition influence drug prices?
Generic entry typically causes list prices to drop by 50% or more, reducing revenues for branded manufacturers and stabilizing retail prices.
2. Are there upcoming patent protections that could extend pricing power?
Secondary patents and formulation exclusivities could delay generic entry until at least 2023 or 2024, temporarily supporting higher prices.
3. What is the primary driver of sales decline for aliskiren?
Limited adoption due to safety concerns, competition from more established antihypertensives, and market saturation.
4. How might new hypertension therapies affect Tekturna’s market?
Innovations like fixed-dose combinations or novel mechanisms could displace monotherapy products, limiting growth or accelerating decline.
5. What is the outlook for prices if patent protections are not extended?
Prices are expected to decline gradually, stabilizing around USD 2.25–2.50 per tablet, influenced by generic market share and policy environment.
References
- FDA Drug Database. (2023). NDC code 70069-0823. Retrieved from https://www.accessdata.fda.gov
- IQVIA. (2022). Medicines Market Analytics. Hypertension drug sales overview.
- Wolters Kluwer. (2020). Key Patent Timelines for Antihypertensive Drugs.
- GoodRx. (2023). Tekturna (aliskiren) prices. Retrieved from https://www.goodrx.com
- Centers for Medicare & Medicaid Services. (2022). National Drug Reimbursement policy updates.
